Branding & Marketing
liver focus for web_1.jpg
SupplementsFTC approves final action related to false Hepaxa claimsFTC approves final action related to false Hepaxa claims
BASF, U.S. distributor made deceptive claims about the supplement’s ability to reduce liver fat in people with non-alcoholic fatty liver disease (NAFLD)
Subscribe for the latest consumer trends, trade news, nutrition science and regulatory updates in the supplement industry!
Join 37,000+ members. Yes, it's completely free.